# Celgene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/celgene

- Industry: Biotechnology
- Headquarters: Summit, US
- Website: www.celgene.com
- Total disclosed funding: $9M
- Latest round: Series A (Feb 15, 2007)
- Investors on record: 4

## About

Celgene is a biopharmaceutical company focused on discovering, developing, and delivering innovative therapies for serious diseases, particularly in oncology and immunology, enhancing patient outcomes through cutting-edge treatments.Celgene is a biopharmaceutical company that specializes in developing therapies primarily for cancer and immune-related conditions. The company was founded by Haley Branch and is headquartered in Summit, New Jersey, US. In January 2019, Bristol-Myers Squibb Company agreed to acquire Celgene for USD 74 billion in a cash and stock transaction, which will enable Bristol-Myers Squibb to expand its operations. Celgene's products focus on oncology therapies, including Opdivo (nivolumab) and Yervoy (ipilimumab), enhancing the body's immune response against cancer. They also offer treatments for cardiovascular disease, such as Eliquis (apixaban), and autoimmune diseases with therapies like Orencia (abatacept). Their client base includes healthcare providers and specialty pharmacies across North America, Europe, and Asia-Pacific.Celgene generates revenue through direct sales of its pharmaceutical products to healthcare providers and institutions globally. Its key products, including Opdivo and Eliquis, are typically supplied through wholesale distributors to hospitals and clinics, reflecting their critical role in patient treatment regimens.Celgene's future growth strategy involves leveraging the recent acquisition by Bristol-Myers Squibb to enhance its portfolio and expand into new markets. The acquisition, finalized on January 3, 2019, for USD 74 billion, is expected to support the development of new products in oncology and immunology. The company aims to target expansion into emerging markets in Asia and Europe by 2025, aligning its product development with unmet medical needs in these regions.

## Funding rounds

- Series A, Feb 15, 2007, $9M — Abingworth, Atlas Venture, Polaris Partners, Advent Venture Partners

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A
- Advent Venture Partners (https://capitalatlas.ai/funds/advent-venture-partners) — Series A